子宫肌瘤与非信息性游离DNA筛查结果的关联
这项回顾性队列研究纳入2013至2020年间接受cfDNA筛查的19818例孕妇,比较有和无子宫肌瘤者的筛查失败风险。肌瘤组非信息性结果发生率为1.96%,无肌瘤组为1.06%(aOR 2.40,95%CI 1.65-3.48),且风险随肌瘤数目和总体积增加而升高。肌瘤组胎儿分数平均低0.61%(95%CI -0.77%至-0.45%)。
要点
- 有子宫肌瘤者cfDNA筛查失败风险升高(aOR 2.40,95%CI 1.65-3.48)。
- 肌瘤数目≥4个者失败风险aOR 5.05(95%CI 2.29-11.13)。
- 肌瘤总体积>400 mL者失败风险aOR 14.80(95%CI 4.50-48.69)。
核心结论
- 子宫肌瘤与较低的胎儿分数及cfDNA筛查失败风险升高相关,且关联强度随肌瘤数目和体积增加而增强。
研究设计与样本
- 回顾性队列研究,纳入2013至2020年间接受cfDNA筛查胎儿染色体异常的孕妇19818例,比较24周前任何产科超声记录有子宫肌瘤与无子宫肌瘤的妊娠。
- 采用单变量和多变量logistic回归分析肌瘤与cfDNA失败的关联,调整采血时孕周、母亲年龄、体重和身高、受孕方式、多胎妊娠及检测平台。
- 按肌瘤数目和总体积进行分层分析;采用线性回归评估肌瘤对胎儿分数的影响,调整相同协变量。
主要发现
- 19818例接受cfDNA筛查的妊娠中,2038例(10.28%)报告有子宫肌瘤,228例(1.15%)在首次筛查尝试中cfDNA失败。
- 有肌瘤妊娠非信息性结果发生率为1.96%,无肌瘤妊娠为1.06%(aOR 2.40,95%CI 1.65-3.48)。
- 首次筛查失败风险随肌瘤数目增加而升高,≥4个肌瘤者aOR 5.05(95%CI 2.29-11.13)。
- 肌瘤总体积100.1-400 mL者aOR 5.52(95%CI 2.30-13.25),>400 mL者aOR 14.80(95%CI 4.50-48.69)。
- 与无肌瘤妊娠相比,有肌瘤妊娠胎儿分数平均低0.61%(调整后均值差-0.61%,95%CI -0.77%至-0.45%)。
关键数值与推荐
- 有肌瘤妊娠非信息性结果发生率1.96%,无肌瘤妊娠1.06%(aOR 2.40,95%CI 1.65-3.48)。
- ≥4个肌瘤者首次筛查失败aOR 5.05(95%CI 2.29-11.13)。
- 肌瘤总体积100.1-400 mL者aOR 5.52(95%CI 2.30-13.25),>400 mL者aOR 14.80(95%CI 4.50-48.69)。
- 有肌瘤妊娠胎儿分数平均低0.61%(调整后均值差-0.61%,95%CI -0.77%至-0.45%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Uterine fibroids are monoclonal tumors, which are often genetically abnormal and associated with false-positive genome-wide cell-free DNA (cfDNA) screening results, particularly when large. It is plausible that fibroids may also increase the risk of cfDNA failure by affecting fetal fraction or due to their genetic anomalies confounding cfDNA algorithms. We aimed to investigate a possible association between fibroids and cfDNA non-informative results. METHODS: This was a retrospective cohort study of women undergoing cfDNA screening for fetal chromosomal abnormalities between 2013 and 2020, comparing pregnancies with vs without uterine fibroids recorded on any obstetric ultrasound before 24 weeks' gestation. Univariable and multivariable logistic regression models were used to investigate the association between fibroids and cfDNA failure, adjusting for gestational age, maternal age, weight and height at blood sampling, mode of conception, multiple gestation and test platform (chromosome-selective or genome-wide). Analyses were stratified according to the number of fibroids and total fibroid volume. The impact of fibroids on fetal fraction was assessed using linear regression, adjusting for the same covariates. RESULTS: Among 19 818 pregnancies undergoing cfDNA screening, fibroids were reported in 2038 (10.28%) and cfDNA failure at the first screening attempt occurred in 228 (1.15%) pregnancies. Non-informative results occurred in 1.96% of pregnancies with fibroids and 1.06% of pregnancies without fibroids (adjusted odds ratio (aOR), 2.40 (95% CI, 1.65-3.48)). The risk of failure in the first screening attempt increased progressively with the number of fibroids (aOR, 5.05 (95% CI, 2.29-11.13) in women with four or more fibroids) and total fibroid volume, with greater than a 5-fold and 14-fold increase in risk among women with fibroid volumes of 100.1-400 mL (aOR, 5.52 (95% CI, 2.30-13.25)) and > 400 mL (aOR, 14.80 (95% CI, 4.50-48.69)), respectively. Although test failure was more common with chromosome-selective than genome-wide screening, fibroids similarly increased the risk of failure of both screening platforms. Compared to pregnancies without fibroids, those with fibroids had a fetal fraction on average 0.61% lower (adjusted mean difference, -0.61% (95% CI, -0.77% to -0.45%)). CONCLUSION: Uterine fibroids are associated with lower fetal fraction and an increased risk of cfDNA screening failure. The strength of this association increases with increasing fibroid number and volume. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Rolnik DL, Raymond Y, Lee T, et al. Uterine fibroids and non-informative cell-free DNA screening results. Ultrasound Obstet Gynecol. 2024. PMID: 39177335. doi:10.1002/uog.29098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。